- Home
- QXO vs ARWR Comparison
QXO vs ARWR Comparison
Compare QXO & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QXO | ARWR |
|---|---|---|
| Founded | 1988 | 2003 |
| Country | United States | United States |
| Employees | 7794 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 10.2B |
| IPO Year | N/A | 2009 |
Fundamental Metrics
Financial Performance| Metric | QXO | ARWR |
|---|---|---|
| Price | $16.92 | $79.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 10 |
| Target Price | $32.85 | ★ $83.40 |
| AVG Volume (30 Days) | ★ 16.1M | 1.5M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 99.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,142,321.00 |
| Revenue This Year | $70.27 | N/A |
| Revenue Next Year | $38.75 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.75 | $14.30 |
| 52 Week High | $27.61 | $84.55 |
Technical Indicators
Market Signals| Indicator | QXO | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 48.40 | 57.26 |
| Support Level | $15.43 | $70.05 |
| Resistance Level | $17.96 | $82.26 |
| Average True Range (ATR) | 0.97 | 3.83 |
| MACD | 0.17 | 0.55 |
| Stochastic Oscillator | 63.85 | 68.16 |
Price Performance
Historical ComparisonAbout QXO QXO Inc.
QXO Inc is a publicly traded distributor of building products in North America. The company is executing its plan to become the tech-enabled leader in the around $800 billion building products distribution industry and generate outsized value for its shareholders. The group expects to achieve its target of nearly $50 billion in annual revenues within the next decade through accretive acquisitions and organic growth.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.